NCT01588821View on ClinicalTrials.gov

Cabozantinib in Advanced Solid Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

June 30, 2019

Conditions
Lung CancerSolid Tumor (Not Breast or Prostate Cancers)
Interventions
DRUG

Cabozantinib

60 mg daily by mouth

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01588821 - Cabozantinib in Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter